Novartis AG (NVS)
After hours:
| Previous close | 102.09 |
| Open | 101.52 |
| Bid | 100.00 x 800 |
| Ask | 102.43 x 800 |
| Day's range | 101.03 - 101.77 |
| 52-week range | 74.09 - 105.61 |
| Volume | |
| Avg. volume | 1,339,001 |
| Market cap | 209.184B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 28.09 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.50 (3.38%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
- GlobeNewswire
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolioBasel, September 18, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today ann
- GlobeNewswire
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off Novartis shareholders and Novartis ADR holders will receive one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs through the distribution of a dividend-in-kindThe Spin-off is planned to occur on or around October 4, 2023 Basel, September 15, 2023 — At an Extraord
- GlobeNewswire
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to interleukin (IL)-12/23, approved for treatment of plaque psoriasis, psoriatic arthritis, Crohn´s disease and ulcerative colitis Deal further strengthens Sandoz position in immunology and supports further pipeline expansion Basel, September 11, 2023 — Sandoz, a global leader in generic and biosimilar medicines,
